In the first of a two-part podcast episode, Jeremie Calais, M.D., and Robert Flavell, M.D., discuss recent advances with PSMA-targeted radiotracers in the treatment of metastatic castration-resistant prostate cancer (mCRPC), and the role of imaging criteria in monitoring patients treated with PSMA-targeted radionuclide therapy.